Amwill Health Care Ltd Stock Price Today (NSE: AMWILL)
Fundamental Score
Amwill Health Care Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Amwill Health Care Ltd share price today is ₹43.00, up +1.18% on NSE/BSE as of 3 August 2026. Amwill Health Care Ltd (AMWILL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹82.01 (Cr). The 52-week high for AMWILL share price is ₹65.20 and the 52-week low is ₹28.91. At a P/E ratio of 7.18x, AMWILL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 15.25% and a debt-to-equity ratio of 0.00.
Amwill Health Care Ltd Share Price Chart — NSE/BSE Historical Performance
Amwill Health Care Ltd share price chart: -3.41% return over the past month. 52-week high ₹65.20, 52-week low ₹28.91.
Amwill Health Care Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹42.50 | ₹42.50 | ₹42.50 | ₹42.50 | 2.40K (Cr) | |
| ₹42.99 | ₹42.99 | ₹42.79 | ₹42.79 | 2.40K (Cr) | |
| ₹39.60 | ₹41.49 | ₹39.60 | ₹41.00 | 4.80K (Cr) | |
| ₹38.60 | ₹43.10 | ₹38.60 | ₹40.01 | 6.00K (Cr) | |
| ₹42.50 | ₹42.50 | ₹41.00 | ₹41.58 | 3.60K (Cr) | |
| ₹41.43 | ₹41.43 | ₹41.43 | ₹41.43 | 0.00 (Cr) | |
| ₹42.75 | ₹43.49 | ₹40.60 | ₹41.43 | 19.20K (Cr) | |
| ₹43.50 | ₹44.00 | ₹42.75 | ₹42.75 | 6.00K (Cr) | |
| ₹45.60 | ₹45.60 | ₹42.00 | ₹43.39 | 4.80K (Cr) | |
| ₹41.10 | ₹44.00 | ₹41.10 | ₹42.11 | 8.40K (Cr) |
Amwill Health Care Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹43.00 | ₹45.60 | ₹38.60 | ₹42.50 | -1.16% | |
| ₹34.33 | ₹49.75 | ₹34.33 | ₹44.00 | +28.17% | |
| ₹35.48 | ₹36.40 | ₹30.69 | ₹32.70 | -7.84% | |
| ₹29.50 | ₹38.50 | ₹28.91 | ₹34.89 | +18.27% | |
| ₹33.15 | ₹36.98 | ₹28.95 | ₹28.95 | -12.67% | |
| ₹35.96 | ₹37.79 | ₹34.50 | ₹34.85 | -3.09% | |
| ₹48.90 | ₹50.90 | ₹36.25 | ₹39.55 | -19.12% | |
| ₹42.05 | ₹47.94 | ₹34.00 | ₹47.63 | +13.27% | |
| ₹56.00 | ₹57.00 | ₹40.00 | ₹42.05 | -24.91% | |
| ₹53.30 | ₹55.96 | ₹50.00 | ₹54.00 | +1.31% | |
| ₹58.99 | ₹62.99 | ₹53.01 | ₹53.24 | -9.75% | |
| ₹60.00 | ₹65.20 | ₹55.00 | ₹55.77 | -7.05% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Dirt-cheap P/E and soaring earnings are completely neutralized by micro-cap illiquidity and a reconstructed database audit warning.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Amwill Health Care announced its 9th Annual General Meeting scheduled for August 14, 2026, alongside a recommended final dividend of ₹0.50 per share. The company recently parked surplus internal accruals into a ₹2 crore fixed deposit with Vysya Co-operative Bank approved on July 23, 2026. FY26 net profit jumped 79% year-on-year to ₹11.42 crore on operational revenue of ₹45.49 crore. Auditors issued an unmodified opinion but flagged a severe prior cyber security incident from February 2026 that destroyed primary electronic backups, forcing manual database reconstruction.
CORE STORY (THE REAL GAME)
A micro-cap derma contract manufacturing player trading at single-digit P/E masking deep structural liquidity evaporation and historical data integrity scars.
- AGM scheduled for August 14, 2026 with a ₹0.50 final dividend record date approaching
- Deployment of ₹2 crore into fixed deposits signaling surplus cash accumulation
- FY26 earnings release showing 79% jump in net profit to ₹11.42 crore
- Sustained quarterly margin expansion above 30% OPM
- Institutional buying emergence to clear the zero FII/DII barrier
- Transparent resolution and clearance of all IT infrastructure audit flags
- Severe micro-cap liquidity risk with abysmal daily traded volumes
- Auditor-highlighted data loss from a February 2026 cyber incident requiring manual reconstruction
- Zero institutional interest with 1.16% FII exit over recent quarters
Promoters hold 70.65% with zero pledging, but institutional ownership is completely vacant at 0.0% after FII cut allocation.
Domestic Indian pharma demonstrates stable 7 to 9 percent growth with strong tailwinds in specialty and dermatology formulations.
No major contract announcements found; company parked ₹2 crore surplus into fixed deposits on July 23, 2026.
yes
Range-bound consolidation near current levels as micro-cap liquidity constraints stall major upside momentum.
Primary Thesis Risk
Absolute inability to exit large blocks due to extreme micro-cap illiquidity and thin order books.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Amwill Health Care Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Amwill Health Care Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AMWILL across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (15.25%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.51%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.55%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 7.18 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (79.33%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (39.36%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (21.43% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (15.07% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (68.09% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (70.65%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Amwill Health Care Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Amwill Health Care Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Amwill Health Care LtdAmwill Health C...Selected✓ AMWILL • 544353 | 78/100 | ₹43.00₹43 | ₹82.01₹82.01 | 7.18Average 7.2 Average | 15.25%Good 15.25% Good | 20.51%Excellent 20.51% Excellent | 0.00Excellent 0.0 Excellent | 68.09%Excellent 68.09% Excellent | 21.43%Excellent 21.43% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Amwill Health Care Ltd Quarterly Performance
Latest quarterly metrics for AMWILL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
39.36%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
79.33%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
21.43%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
68.09%
Compounded annual net profit growth over 5 years
Amwill Health Care Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AMWILL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Amwill Health Care Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Amwill Health Care Ltd (AMWILL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Amwill Health Care Ltd
About AMWILL (Amwill Health Care Ltd)
Amwill Health Care Ltd is a pharmaceutical enterprise dedicated to innovating and delivering advanced healthcare solutions. With a strong commitment to research and development, AM...WILL focuses on creating novel therapeutic interventions and improving existing treatment modalities across various medical disciplines. The company is structured around a multifaceted approach, encompassing the entire lifecycle of pharmaceutical products, from initial discovery and preclinical studies to clinical trials, regulatory approvals, manufacturing, and commercialization. AMWILL's core strength lies in its team of experienced scientists, clinicians, and industry professionals who collaborate to address unmet medical needs and enhance patient outcomes. Through strategic partnerships and a continuous pursuit of scientific excellence, AMWILL strives to be a catalyst for progress in the ever-evolving landscape of healthcare. AMWILL Health Care Ltd distinguishes itself through its state-of-the-art manufacturing facilities and rigorous quality control processes, ensuring that its products consistently meet the highest standards of safety and efficacy. The company's diverse portfolio includes a wide array of pharmaceutical formulations, catering to a broad spectrum of therapeutic areas, including but not limited to, cardiovascular health, oncology, neurology, and infectious diseases. By embracing cutting-edge technologies and adhering to stringent regulatory guidelines, AMWILL ensures that its offerings are not only effective but also accessible to patients worldwide. The company actively invests in building a robust distribution network and fostering strong relationships with healthcare providers, aiming to facilitate the seamless delivery of its products to those who need them most. Amwill Health Care Ltd is dedicated to corporate social responsibility, understanding that its role extends beyond providing medicines to fostering a healthier and more sustainable future. Through various initiatives, AMWILL actively supports community health programs, promotes environmental conservation, and upholds ethical business practices. The company is committed to transparency and accountability in all its operations, striving to earn the trust and respect of its stakeholders. By prioritizing innovation, quality, and social impact, AMWILL aims to be a trusted partner in healthcare, contributing to the well-being of individuals and communities around the globe. Its overarching goal is to transform lives through its commitment to pharmaceutical excellence and responsible corporate citizenship.
Company Details
Key Leadership
Latest News
AMWILL Share Price: Frequently Asked Questions
What is the current share price of Amwill Health Care Ltd?
Amwill Health Care Ltd (AMWILL) trades at ₹43.00 on NSE and BSE. Market cap ₹82.01 (Cr). Educational data only.
What is the P/E ratio of Amwill Health Care Ltd?
Amwill Health Care Ltd has a P/E of 7.18x vs industry average 34.89x.
What is the Bull Run score for Amwill Health Care Ltd?
Amwill Health Care Ltd has a Bull Run score of 78/100 based on 25+ financial parameters.
Does Amwill Health Care Ltd pay dividends?
Amwill Health Care Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Amwill Health Care Ltd?
Amwill Health Care Ltd has ROE of 15.25%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Amwill Health Care Ltd?
Amwill Health Care Ltd has debt-to-equity of 0.00.
Is Amwill Health Care Ltd a good investment?
Bull Run gives Amwill Health Care Ltd a score of 78/100. This is not investment advice — consult a SEBI-registered advisor.